ABERA BIOSCIENCE AB (F:8WK) — Market Cap & Net Worth
Market Cap & Net Worth: ABERA BIOSCIENCE AB (8WK)
ABERA BIOSCIENCE AB (F:8WK) has a market capitalization of $14.33 Million (€12.26 Million) as of September 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #26208 globally and #2248 in its home market, demonstrating a -8.56% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ABERA BIOSCIENCE AB's stock price €0.60 by its total outstanding shares 20498949 (20.50 Million). Also see total assets of ABERA BIOSCIENCE AB for a full breakdown of the balance sheet.
ABERA BIOSCIENCE AB Market Cap History: 2021 to 2026
ABERA BIOSCIENCE AB's market capitalization history from 2021 to 2026. Data shows change from $20.47 Million to $14.33 Million (-11.43% CAGR). Also see ABERA BIOSCIENCE AB (8WK) cash flow conversion for how efficiently the company converts equity into cash flow.
ABERA BIOSCIENCE AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ABERA BIOSCIENCE AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check today's stock price for ABERA BIOSCIENCE AB for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 8WK by Market Capitalization
Companies near ABERA BIOSCIENCE AB in the global market cap rankings as of September 19, 2026. Review ABERA BIOSCIENCE AB tangible book value ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to ABERA BIOSCIENCE AB by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $128.84 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #340 globally with a market cap of $79.38 Billion USD.
- CSL Ltd (AU:CSL): Ranked #459 globally with a market cap of $60.28 Billion USD ( AU$85.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $128.84 Billion | $508.34 |
| #340 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.38 Billion | $784.85 |
| #459 | CSL Ltd | AU:CSL | $60.28 Billion | AU$175.59 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $154.04 |
ABERA BIOSCIENCE AB Historical Marketcap From 2021 to 2026
Between 2021 and today, ABERA BIOSCIENCE AB's market cap moved from $20.47 Million to $ 14.33 Million, with a yearly change of -11.43%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €14.33 Million | +6.79% |
| 2025 | €13.42 Million | +60.92% |
| 2024 | €8.34 Million | -10.31% |
| 2023 | €9.30 Million | +16.17% |
| 2022 | €8.00 Million | -60.89% |
| 2021 | €20.47 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of ABERA BIOSCIENCE AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $14.33 Million USD |
| MoneyControl | $14.33 Million USD |
| MarketWatch | $14.33 Million USD |
| marketcap.company | $14.33 Million USD |
| Reuters | $14.33 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ABERA BIOSCIENCE AB
Abera Bioscience AB, a platform and vaccine development company, research, design, and develops vaccines and immunotherapies based on its proprietary vaccine delivery platform in Sweden and internationally. The company's development platform named BERA, uses for the display of antigens at the surface of outer membrane vesicles derived from genetically optimized gram-negative bacteria. Its lead va… Read more